SPOCK1表現能預測攝護腺癌預後
王紹全1, 2、宋文瑋3, 4, 5, 6、陳志榮3, 4, 6、張浤榮1, 7
1中山醫學大學醫研所
2中山醫學大學附設醫院泌尿科
3彰化基督教醫院病理科
4中山醫學大學醫學院
5中山醫學大學醫教部
6仁德醫護管理專科學校醫技系
7中山醫學大學附設醫院腎臟科
SPOCK1 Expression Predicts Prognosis in Prostate Cancer
Shao-Chuan Wang1, 2, Wen-Wei Sung3, 4, 5, 6, Chih-Jung Chen3, 4, 6, Horng-Rong Chang1, 7
1Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
2Department of Urology, Chung Shan University Hospital, Taichung, Taiwan
3Department of Surgical Pathology, Changhua Christian Hospital, Changhua, Taiwan
4School of Medicine, Chung Shan Medical University, Taichung, Taiwan
5Department of Medical Education, Chung Shan Medical University Hospital, Taichung, Taiwan
6Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan
7Department of Nephrology, Chung Shan Medical University Hospital, Taichung, Taiwan
Abstract
Background: Prostate cancer is a common cancer and it can often be treated successfully. The 15-year survival rate is more than 90% in patients with early stage, However, once the tumor metastasis occurred, the prognosis got significantly worse.Therefore, to identify patients with malignant potential while diagnosing might improve clinical outcome. The aim of this study was to evaluate the expression of SPOCK1 (sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1) and its clinical significance in prostate cancer.
Materials and methods: SPOCK1 expression was measured by immunohistochemical staining of samples from 71 patients with prostate cancer. The correlation between SPOCK1 expression and clinicopathological features was quantitatively analyzed. The prognostic value of SPOCK1 for overall survival was determined by Kaplan-Meier analysis and Cox proportional hazard models. For underlying molecular mechanism, prostate cancer cell lines were used and SPOCK1 expression was knock-down via siRNA. Migration and invasion assay were performed to determined the tumor malignancy. The downstream signaling pathway will be analyzed with real-time RT-PCR and western blot.
Results: Seventy-one patients with mean age of 74.4 years (range 59 to 97 years) were included. Clinicopathological features, including histological type, differentiation, lymph node metastasis, TNM stage, and tumor size were assessed. Patients with high SPOCK1 expression were more prone to be advanced stage. As to the prognosis, the median follow-up for overall survival was 5.2±2.9 years (range: 0.7 to 11.8 years). Moreover, a high POCK1 expression level was correlated with poor survival. The underlying mechanism is under investigation.
Conclusions: Our results suggest that SPOCK1 expression is enhanced in prostate cancer. High SPOCK1 expression, either alone or in combination with other pathologic staging factors, may therefore serve as a poor prognostic marker for prostate cancer.